Ocera Therapeutics (Ocera Therapeutics) Short-Term Debt & Capital Lease Obligation : $7.37 Mil (As of Sep. 2017)

View and export this data going back to 2011. Start your Free Trial

What is Ocera Therapeutics Short-Term Debt & Capital Lease Obligation?

Short-Term Debt & Capital Lease Obligation is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt. Ocera Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2017 was $7.37 Mil.

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. Ocera Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2017 was $0.00 Mil.

Ocera Therapeutics Short-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for Ocera Therapeutics's Short-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocera Therapeutics Short-Term Debt & Capital Lease Obligation Chart

Ocera Therapeutics Annual Data

Trend

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Short-Term Debt & Capital Lease Obligation

Get a 7-Day Free Trial

2.91

9.70

Ocera Therapeutics Quarterly Data
	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17
Short-Term Debt & Capital Lease Obligation	Get a 7-Day Free Trial															1.96	9.70	9.15	8.27	7.37

Ocera Therapeutics Short-Term Debt & Capital Lease Obligation Calculation

This is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt.

In the notes to balance sheet in annual (10-K) or quarterly (10-Q) reports, companies usually break down the details of the debt, their due dates, the interest rates etc.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Ocera Therapeutics Short-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Ocera Therapeutics's Short-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Ocera Therapeutics (Ocera Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocera Therapeutics Inc (NAS:OCRX) » Definitions » Short-Term Debt & Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

525 University Avenue, Suite 610, Palo Alto, CA, USA, 94301

Website

http://www.ocerainc.com

Ocera Therapeutics Inc is a clinical-stage biopharmaceutical company, which primarily targets acute and chronic orphan liver diseases. The company is focused on the development and commercialization of a clinical product candidate, OCR-002 for the treatment of acute and chronic hepatic encephalopathy for patients with a serious complication of liver cirrhosis, or liver failure, marked by mental changes including confusion, impaired motor skills, disorientation in time and space, and, in its more severe form, stupor, coma and even death. All the business activity of the firm is functioned through the region of US.

Executives

Brian H Dovey	10 percent owner	ONE PALMER SQUARE, PRINCETON NJ 08542
Steven P James	director	C/O OCERA THERAPUETICS, 525 UNIVERSITY AVENUE, SUITE 610, PALO ALTO CA 94301
Wendall Wierenga	director	12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130
Nina S Kjellson	director	C/O INTERWEST PARTNERS, 2710 SAND HILL ROAD, SUITE 200, MENLO PARK CA 94025
Domain Partners Viii, L.p.	10 percent owner	C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542
Dp Viii Associates, L.p.	10 percent owner	C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542
Eckard Weber	director	C/O DOMAIN ASSOCIATES, ONE PALO SQ, PRINCETON NJ 08542
Kim P. Kamdar	10 percent owner	C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542
Brian K Halak	10 percent owner	C/O DOMAIN ASSOCIATES, ONE PALMER SQUARE, PRINCETON NJ 08542
Dp Vi Associates, L.p.	10 percent owner	ONE PALMER SQUARE, PRINCETON NJ 08542
Associates Domain	10 percent owner	ONE PALMER SQUARE, PRINCETON NJ 08542
Domain Partners Vi, L.p.	10 percent owner	ONE PALMER SQUARE, PRINCETON NJ 08542
Nicole Vitullo	10 percent owner	3030 SCIENCE PARK ROAD, SAN DIEGO CA 92121
James C Blair	10 percent owner	5880 PACIFIC CENTER BLVD, SAN DIEGO CA 92121-4204
Jesse I Treu	10 percent owner

Ocera Therapeutics (Ocera Therapeutics) Headlines

From GuruFocus

Top 3 Insider Buys of the Week

By Monica Wolfe Monica Wolfe • 07-19-2013

Three Insider Buys at 52-Week Lows

By Monica Wolfe Monica Wolfe • 07-22-2014